This study will evaluate D1 Receptor Occupancy (RO) following a single dose of PF-06412562 In healthy male volunteers
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
5
Subject will receive a single dose of 30 mg PF-06412562
The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2. This Cohort is optional.
Karolinska Trial Alliance (KTA) M62
Huddinge, Stockholm County, Sweden
PF-06142562 plasma exposure and RO in the striatum
Using Positron Emission Tomography and a radiotracer \[11C\]SCH23390, the PF-06142562 plasma exposure and RO in the striatum (average of caudate and putamen) will be measured in healthy male subjects.
Time frame: Day 1
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Day 1
Area under the plasma concentration-time profile from time zero to the last plasma measurement at 4 hours (AUC0-4)
Time frame: Day 1
Average plasma concentration over 4 hours (Cav,0-4)
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.